Sigilon Therapeutics Inc. (SGTX): Price and Financial Metrics


Sigilon Therapeutics Inc. (SGTX): $0.81

0.04 (+5.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SGTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SGTX POWR Grades


  • Sentiment is the dimension where SGTX ranks best; there it ranks ahead of 79.75% of US stocks.
  • The strongest trend for SGTX is in Quality, which has been heading down over the past 123 days.
  • SGTX's current lowest rank is in the Momentum metric (where it is better than 9.26% of US stocks).

SGTX Stock Summary

  • Sigilon Therapeutics Inc's stock had its IPO on December 4, 2020, making it an older stock than merely 1.72% of US equities in our set.
  • Revenue growth over the past 12 months for Sigilon Therapeutics Inc comes in at -28.23%, a number that bests only 5.84% of the US stocks we're tracking.
  • In terms of volatility of its share price, SGTX is more volatile than 97.61% of stocks we're observing.
  • Stocks that are quantitatively similar to SGTX, based on their financial statements, market capitalization, and price volatility, are AYLA, STTK, CLLS, TMDI, and VBLT.
  • Visit SGTX's SEC page to see the company's official filings. To visit the company's web site, go to sigilon.com.

SGTX Valuation Summary

  • SGTX's price/earnings ratio is -3.5; this is 109.59% lower than that of the median Healthcare stock.
  • Over the past 39 weeks, SGTX's price/sales ratio has gone down 56.5.
  • SGTX's price/sales ratio has moved down 56.5 over the prior 39 weeks.

Below are key valuation metrics over time for SGTX.

Stock Date P/S P/B P/E EV/EBIT
SGTX 2021-08-31 14.2 1.7 -3.5 -1.2
SGTX 2021-08-30 14.0 1.7 -3.4 -1.1
SGTX 2021-08-27 14.4 1.7 -3.5 -1.2
SGTX 2021-08-26 13.5 1.6 -3.3 -1.0
SGTX 2021-08-25 13.5 1.6 -3.3 -1.0
SGTX 2021-08-24 13.0 1.6 -3.2 -0.8

SGTX Price Target

For more insight on analysts targets of SGTX, see our SGTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.75 Average Broker Recommendation 1.38 (Strong Buy)

SGTX Stock Price Chart Interactive Chart >

Price chart for SGTX

SGTX Price/Volume Stats

Current price $0.81 52-week high $12.55
Prev. close $0.76 52-week low $0.73
Day low $0.77 Volume 100,100
Day high $0.82 Avg. volume 93,291
50-day MA $1.19 Dividend yield N/A
200-day MA $3.11 Market Cap 26.17M

Sigilon Therapeutics Inc. (SGTX) Company Bio


Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.


SGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

SGTX Latest Social Stream


Loading social stream, please wait...

View Full SGTX Social Stream

Latest SGTX News From Around the Web

Below are the latest news stories about Sigilon Therapeutics Inc that investors may wish to consider to help them evaluate SGTX as an investment opportunity.

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022. Dr. Yuan brings more than 20 years of experience in process development, manufacturing sciences and CMC strategies from a broad range of leading biop

Yahoo | February 22, 2022

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report preliminary fourth quarter and full year 2021 financial results and full year 2022 financial guidance after the market closes on Monday, February 28, 2022. Jack Khattar, President and CEO, and Tim Dec, Senior Vice

Yahoo | February 22, 2022

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it received notice from the U.S. Food and Drug Administration (FDA) that the company’s New Drug Application (NDA) resubmission for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in P

Yahoo | February 22, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

Yahoo | February 15, 2022

Bears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' Now

Sigilon Therapeutics, Inc. (SGTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | February 7, 2022

Read More 'SGTX' Stories Here

SGTX Price Returns

1-mo -22.86%
3-mo -44.14%
6-mo -78.46%
1-year -93.06%
3-year N/A
5-year N/A
YTD -70.65%
2021 -94.25%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5203 seconds.